Notice of Intent to Increase Ceiling of IDIQ for operations and maintenance (O&M) support services at the FDA-owned Muirkirk Road Complex (MRC)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA) has issued a Special Notice announcing its intent to award a sole source contract modification to NVE, Inc. This modification will increase the ceiling of the existing Indefinite Delivery/Indefinite Quantity (IDIQ) bridge contract (No. 75F40124D00066) by $3.2 million. The purpose is to ensure continued 24/7 operations and maintenance (O&M) support services at the FDA-owned Muirkirk Road Complex (MRC) in Laurel, Maryland, for a four-month extension period.
Purpose
This ceiling increase is required to cover essential mission-critical O&M services during a four-month extension. This extension will bridge the gap while the FDA completes the competitive acquisition process for a long-term follow-on contract for these services.
Contract Details
- Type: Sole Source Contract Modification (to existing IDIQ)
- Current Contractor: NVE, Inc., 13800 Coppermine Road, Suite 301, Herndon, VA 20171
- Contract Number: 75F40124D00066
- Ceiling Increase: $3.2 million
- Services: 24/7 Operations and Maintenance (O&M) support services
- Place of Performance: FDA-owned Muirkirk Road Complex (MRC), Laurel, MD, United States
- Product/Service Code: S216 - Facilities Operations Support Services
- Department/Agency: Health And Human Services / Food And Drug Administration
Set-Aside
No set-aside is specified as this is a notice of intent for a sole source modification.
Response & Timeline
- Notice Published: March 5, 2026
- Response Date: March 11, 2026, 6:00 PM ET
- Action: Interested parties who believe they can meet the requirement may submit a capabilities statement by the response date.
Contact Information
- Primary: Sarah Hussain (Sarah.Hussain@fda.hhs.gov)
- Secondary: L. Maria Finan (Linda.Finan@fda.hhs.gov, 1-240-402-5712)